No­vo Nordisk, one of the world’s top three man­u­fac­tur­ers of in­sulin, agreed to pay $100 mil­lion to set­tle a 2017 in­vestor suit that al­leged the com­pa­ny failed to dis­close that it was un­der the same pric­ing pres­sures as its com­peti­tors.

No­vo said in a state­ment on Fri­day the set­tle­ment was reached af­ter a vol­un­tary me­di­a­tion process and re­solves claims brought on by in­vestors for al­leged vi­o­la­tions of US se­cu­ri­ties laws. The com­pa­ny said the set­tle­ment con­tains no ad­mis­sion of li­a­bil­i­ty, wrong­do­ing or re­spon­si­bil­i­ty by any of the de­fen­dants.

But the set­tle­ment fur­ther ex­pos­es how the mid­dle­men, known as phar­ma­cy ben­e­fit man­agers, have al­tered the course of in­sulin pric­ing as prices have in­creased for di­a­bet­ics and man­u­fac­tur­ers’ prof­its have de­clined.

The in­vestors’ com­plaint al­leged that “No­vo Nordisk was able to raise the price of its in­sulin drugs 450% above the rate of in­fla­tion. From 2010-2015, the Com­pa­ny raised the price of its sig­na­ture di­a­betes drug (Lev­emir) by 169%. In 2014-2015 alone the Com­pa­ny in­creased Lev­emir’s price by 30%, and in­creased the price of its No­voLog prod­uct by near­ly 21%. As No­vo Nordisk re­cent­ly ad­mit­ted, these price in­creas­es were so sig­nif­i­cant that ‘many pa­tients sim­ply can’t af­ford the med­i­cine they need.'”

But those price in­creas­es were not enough, as the com­pa­ny in Oct. 2016 cut its long-term prof­it growth fore­casts by 50%, specif­i­cal­ly cit­ing in­creased pric­ing pres­sures on di­a­betes drugs.

One month lat­er, Sen. Bernie Sanders (D-VT) and the late Rep. Eli­jah Cum­mings (D-MD) sent a let­ter to the De­part­ment of Jus­tice, call­ing on fed­er­al an­titrust reg­u­la­tors to probe il­le­gal col­lu­sion by No­vo Nordisk and the oth­er ma­jor in­sulin pro­duc­ers —Sanofi, Eli Lil­ly, and Mer­ck — to set the prices for in­sulin and oth­er di­a­betes drugs.

The in­vestors not­ed in their com­plaint that in 13 in­stances since 2009, the prices of No­vo’s Lev­emir and Sanofi’s Lan­tus have in­creased in tan­dem in the US.

No­vo Nordisk pledged on Nov. 30, 2016, to lim­it all fu­ture drug list price in­creas­es to sin­gle-dig­it per­cent­ages. But in the four years since then, law­mak­ers are still try­ing to find a way to nail the com­pa­nies on col­lu­sive price in­creas­es.

Six House De­moc­rats in March sent a let­ter to the FTC, call­ing for an in­ves­ti­ga­tion in­to the po­ten­tial col­lu­sion of in­sulin mar­ket lead­ers Eli Lil­ly, Sanofi and No­vo Nordisk.

Steve Holtzman was awoken by a 1 a.m. call from a doctor at Duke University asking if he could put some pigs on a plane and fly them from Ohio to North Carolina that day. A motorcyclist had gotten into a horrific crash, the doctor explained. He believed the pigs’ livers, sutured onto the patient’s skin like an external filter, might be able to tide the young man over until a donor liver became available.

David Livingston, the Dana-Farber/Harvard Med scientist who helped shine a light on some of the key molecular drivers of breast and ovarian cancer, died unexpectedly last Sunday.

One of the senior leaders at Dana-Farber during his nearly half century of work there, Livingston was credited with shedding light on the genes that regulate cell growth, with insights into inherited BRCA1 and BRCA2 mutations that helped lay the scientific foundation for targeted therapies and earlier detection that have transformed the field.

Just as Avoro Capital’s campaign to derail Merck’s proposed $11.5 billion buyout of Acceleron gains steam, Bristol Myers Squibb is leaning in with some hefty counterweight.

The pharma giant is planning to tender its Acceleron shares, Bloomberg reported, which add up to a sizable 11.5% stake. Based on the offer price, the sale would net Bristol Myers around $1.3 billion.

To complete its deal, Merck needs a majority of shareholders to agree to sell their shares.